(Total Views: 121)
Posted On: 07/14/2025 6:32:41 PM
Post# of 8485
BIEL + VLMS + VIANT
Transforming Non-Opioid Pain Relief into a Scalable, Connected Health Solution
Executive Vision
ActiPatch offers a revolutionary, drug-free solution for chronic pain relief using pulsed electromagnetic field (PEMF) therapy. FDA-cleared and clinically validated, ActiPatch meets the growing demand for wearable, non-invasive alternatives to opioids. Through a strategic alliance with Viant Medical and VLMS Healthcare, ActiPatch is primed to scale manufacturing, enable digital transformation, and enter reimbursed clinical and consumer markets.
Product Snapshot
Technology: Pulsed Electromagnetic Field (PEMF)
Applications: Chronic pain—back, joints, knees, post-operative recovery
Safety Profile: No drug interactions, non-invasive, long-term use
Regulatory: FDA predicate clearance
Sales Model: Direct-to-consumer, payer reimbursement, bundled clinical programs
Strategic Partner Roles
Viant Medical (Dr. Sree Koneru)
Lead ActiPatch’s evolution into a connected health device with sensors and mobile app integration
Drive engineering innovation, form factor optimization, and mass scalability
Leverage Viant’s vertically integrated infrastructure to accelerate market entry
VLMS Healthcare (Keith Nalepka)
Execute insurance coding, CMS strategy, and payer engagement for reimbursement
Manage operational infrastructure to support claims, provider onboarding, and lifecycle revenue
Leverage Keith’s prior BioElectronics experience to lead go-to-market execution
BioElectronics Corp
Provide IP, clinical data, and subject matter expertise
Facilitate strategic oversight through leadership ties with Viant and VLMS
Financial Projections
With a retail price of $50 per unit and an 80% profit margin, each device generates $40 profit. Scalable volume targets yield strong returns:
Additional revenue streams:
Subscription-based smart device upgrades
Clinical bundling contracts
Reimbursed recurring therapies
Market Outlook
U.S. Market
Valued at $80.92B in 2025, growing to $96.53B by 2030
Over 1 in 5 Americans experience chronic pain annually
PEMF segment seeing expansion due to demand for opioid-free alternatives
Global Market
Estimated at $75.23B in 2024, forecasted to reach $120.66B by 2033
PEMF therapy devices projected to grow from $755.82M in 2024 to $1.19B by 2033
Growth fueled by digital health innovation, aging populations, and remote therapy demand
Strategic Outcomes
This partnership will unlock:
A connected therapeutic platform for chronic pain relief
Accelerated mass production and global distribution
Access to insurance reimbursement and clinical integration
A high-margin, scalable model positioned at the crossroads of medtech and digital care
Enhanced brand positioning as a credible, data-backed solution to opioid reliance
Transforming Non-Opioid Pain Relief into a Scalable, Connected Health Solution
Executive Vision
ActiPatch offers a revolutionary, drug-free solution for chronic pain relief using pulsed electromagnetic field (PEMF) therapy. FDA-cleared and clinically validated, ActiPatch meets the growing demand for wearable, non-invasive alternatives to opioids. Through a strategic alliance with Viant Medical and VLMS Healthcare, ActiPatch is primed to scale manufacturing, enable digital transformation, and enter reimbursed clinical and consumer markets.
Product Snapshot
Technology: Pulsed Electromagnetic Field (PEMF)
Applications: Chronic pain—back, joints, knees, post-operative recovery
Safety Profile: No drug interactions, non-invasive, long-term use
Regulatory: FDA predicate clearance
Sales Model: Direct-to-consumer, payer reimbursement, bundled clinical programs
Strategic Partner Roles
Viant Medical (Dr. Sree Koneru)
Lead ActiPatch’s evolution into a connected health device with sensors and mobile app integration
Drive engineering innovation, form factor optimization, and mass scalability
Leverage Viant’s vertically integrated infrastructure to accelerate market entry
VLMS Healthcare (Keith Nalepka)
Execute insurance coding, CMS strategy, and payer engagement for reimbursement
Manage operational infrastructure to support claims, provider onboarding, and lifecycle revenue
Leverage Keith’s prior BioElectronics experience to lead go-to-market execution
BioElectronics Corp
Provide IP, clinical data, and subject matter expertise
Facilitate strategic oversight through leadership ties with Viant and VLMS
Financial Projections
With a retail price of $50 per unit and an 80% profit margin, each device generates $40 profit. Scalable volume targets yield strong returns:
Additional revenue streams:
Subscription-based smart device upgrades
Clinical bundling contracts
Reimbursed recurring therapies
Market Outlook
U.S. Market
Valued at $80.92B in 2025, growing to $96.53B by 2030
Over 1 in 5 Americans experience chronic pain annually
PEMF segment seeing expansion due to demand for opioid-free alternatives
Global Market
Estimated at $75.23B in 2024, forecasted to reach $120.66B by 2033
PEMF therapy devices projected to grow from $755.82M in 2024 to $1.19B by 2033
Growth fueled by digital health innovation, aging populations, and remote therapy demand
Strategic Outcomes
This partnership will unlock:
A connected therapeutic platform for chronic pain relief
Accelerated mass production and global distribution
Access to insurance reimbursement and clinical integration
A high-margin, scalable model positioned at the crossroads of medtech and digital care
Enhanced brand positioning as a credible, data-backed solution to opioid reliance
(1)
(0)
